FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment – Investor's Business Daily
Business News
- FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment Investor’s Business Daily
- FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease Yahoo Finance
- While FibroGen and AstraZeneca stumble, cheeky GSK drops competing data for anemia drug FierceBiotech
- AstraZeneca, FibroGen hit another roxadustat setback as FDA panel calls for more safety data FiercePharma
- FibroGen sheds a third after setback for kidney disease therapy in FDA AdCom meeting Seeking Alpha
- View Full Coverage on Google News
Source: Business News